Center for Environmentally
Beneficial Catalysis

  • Home
  • CEBC Colloquium Goes 3D

CEBC Colloquium Goes 3D

Monday, February 16, 2009

Dr. Robert Morton treated CEBC to a memorable, and unusual, colloquium on Feb. 12, 2009

First, Dr. Morton presented his work at ConocoPhillips where he helped to create a commercially viable and environmentally beneficial technology to remove sulfur from Syngas.   By reducing the amount of sulfur to ultra low levels (ppm), the resulting Syngas is much cleaner for power generation and less likely to cause harmful acid rain.  This technology is being licensed to processing plants world-wide. 

But, Dr. Morton also has a unique science hobby – he is an X-ray imaging enthusiast. 

In his spare time, he and his family have imaged fossilized dinosaur bones at NASA and used Stanford’s Linear Accelerator X-ray beam to confirm that an ancient parchment paper was actually the Archimedes Palimpsest.  He has even been on the Discovery Channel talking about this work.


With the help of new X-ray imaging technologies, Dr. Morton has been able to reveal the chemical makeup of different specimens. The cool part is that these images are in 3D, exposing the spatial location of the “Chemical Fossil” record. 

Dr. Morton, materials scientist and licensed pyro-technician, had these words of advice for students:  “You don’t know that what you learn now is going to be valuable later.”


CEBC Calendar

April 12, Wednesday - Mandatory Lab Safety Meeting
All researchers at 1501 Wakarusa Dr. must attend

9:00 a.m. in Building B seminar room

April 24 & 25, Spring IAB/SAB Meeting
Monday, April 24, 11:00 a.m. - 7:30 p.m. at Adams Alumni Center, 1266 Oread Ave.
Tuesday, April 25, 8:00 a.m. - 1:00 p.m. at the CEBC complex, 1501 Wakarusa Drive

April 28, Friday - Shiflett Research Open Laboratory
Tours of facilities & research presentations; light refreshments served
2:00-4:00 p.m., LEEP2 Lab 2444
inquiries: contact


KU Today
48 nationally ranked graduate programs.
—U.S. News & World Report
Pharmacy school No. 2 nationally for NIH funding